# Enoxaparin Metabolism in Reconstructive Surgery Patients

Study · id `cardio:ct-nct02411292` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02411292](<https://clinicaltrials.gov/study/NCT02411292>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02411292

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

## Technical summary

Registry record NCT02411292. Allocation not applicable; no masking; primary purpose other. Start 2015-03 (actual); primary completion 2016-03 (actual). Results posted on 2017-09-13.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose other
- Phase: Phase 2
- Enrolled: 110 participants (enrolled count; ClinicalTrials.gov record NCT02411292, source copy `cardio:ctgov-nct02411292-2018-11-16`, retrieved 2026-10-31)
- Started: 2015-03 (actual) (ClinicalTrials.gov record NCT02411292, source copy `cardio:ctgov-nct02411292-2018-11-16`, retrieved 2026-10-31)
- Primary completion: 2016-03 (actual) (ClinicalTrials.gov record NCT02411292, source copy `cardio:ctgov-nct02411292-2018-11-16`, retrieved 2026-10-31)
- Completion: 2016-06 (actual) (ClinicalTrials.gov record NCT02411292, source copy `cardio:ctgov-nct02411292-2018-11-16`, retrieved 2026-10-31)
- Results first posted: 2017-09-13 (ClinicalTrials.gov record NCT02411292, source copy `cardio:ctgov-nct02411292-2018-11-16`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT02411292, source copy `cardio:ctgov-nct02411292-2018-11-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02411292-2018-11-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: Enoxaparin Metabolism in Reconstructive Surgery Patients
- Condition: Venous Thromboembolism
- Condition: Deep Venous Thrombosis
- Condition: Pulmonary Embolus
- Condition: Reconstructive Surgery
- Intervention (Drug): Enoxaparin
- Lead sponsor: University of Utah
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry intervention name matches this record: Enoxaparin (`core:enoxaparin`)
- Registry lists this organization as the lead sponsor: University of Utah (`cardio:org-university-of-utah`)

## Provenance

Content hash: f508e557bd38a1be95cdb6692a145173245f33b619f4bff3498adf93fb6989f1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
